TY - JOUR
T1 - Animal models of human prostate cancer
T2 - The consensus report of the new york meeting of the mouse models of human cancers consortium prostate pathology committee
AU - Ittmann, Michael
AU - Huang, Jiaoti
AU - Radaelli, Enrico
AU - Martin, Philip
AU - Signoretti, Sabina
AU - Sullivan, Ruth
AU - Simons, Brian W.
AU - Ward, Jerrold M.
AU - Robinson, Brian D.
AU - Chu, Gerald C.
AU - Loda, Massimo
AU - Thomas, George
AU - Borowsky, Alexander
AU - Cardiff, Robert D.
PY - 2013/5/1
Y1 - 2013/5/1
N2 - Animal models, particularly mouse models, play a central role in the study of the etiology, prevention, and treatment of human prostate cancer. While tissue culture models are extremely useful in understanding the biology of prostate cancer, they cannot recapitulate the complex cellular interactions within the tumor microenvironment that play a key role in cancer initiation and progression. The National Cancer Institute (NCI) Mouse Models of Human Cancers Consortium convened a group of human and veterinary pathologists to review the current animal models of prostate cancer and make recommendations about the pathologic analysis of these models. More than 40 different models with 439 samples were reviewed, including genetically engineered mouse models, xenograft, rat, and canine models. Numerous relevant models have been developed over the past 15 years, and each approach has strengths and weaknesses. Analysis of multiple genetically engineered models has shown that reactive stroma formation is present in all the models developing invasive carcinomas. In addition, numerous models with multiple genetic alterations display aggressive phenotypes characterized by sarcomatoid carcinomas and metastases, which is presumably a histologic manifestation of epithelial-mesenchymal transition. The significant progress in development of improved models of prostate cancer has already accelerated our understanding of thecomplex biology of prostate cancer andpromises to enhance developmentof new approaches to prevention, detection, and treatment of this common malignancy. Cancer Res; 73(9); 2718-36.
AB - Animal models, particularly mouse models, play a central role in the study of the etiology, prevention, and treatment of human prostate cancer. While tissue culture models are extremely useful in understanding the biology of prostate cancer, they cannot recapitulate the complex cellular interactions within the tumor microenvironment that play a key role in cancer initiation and progression. The National Cancer Institute (NCI) Mouse Models of Human Cancers Consortium convened a group of human and veterinary pathologists to review the current animal models of prostate cancer and make recommendations about the pathologic analysis of these models. More than 40 different models with 439 samples were reviewed, including genetically engineered mouse models, xenograft, rat, and canine models. Numerous relevant models have been developed over the past 15 years, and each approach has strengths and weaknesses. Analysis of multiple genetically engineered models has shown that reactive stroma formation is present in all the models developing invasive carcinomas. In addition, numerous models with multiple genetic alterations display aggressive phenotypes characterized by sarcomatoid carcinomas and metastases, which is presumably a histologic manifestation of epithelial-mesenchymal transition. The significant progress in development of improved models of prostate cancer has already accelerated our understanding of thecomplex biology of prostate cancer andpromises to enhance developmentof new approaches to prevention, detection, and treatment of this common malignancy. Cancer Res; 73(9); 2718-36.
UR - http://www.scopus.com/inward/record.url?scp=84877785851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877785851&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-12-4213
DO - 10.1158/0008-5472.CAN-12-4213
M3 - Review article
C2 - 23610450
AN - SCOPUS:84877785851
SN - 0008-5472
VL - 73
SP - 2718
EP - 2736
JO - Cancer Research
JF - Cancer Research
IS - 9
ER -